Search
01/01/2023
Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma
Subiela J.D., González-Padilla D.A., Huguet J., Aumatell J., Rodríguez-Faba O., Krajewski W., Feliu A.H., Mínguez C., Plaza J.L., Artiles Medina A., Gajate P., Jiménez Cidre M.Á., Burgos Revilla J., Breda A., Palou J.. Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma. UROLOGY. 2023; 172DOI:10.1016/j.urology.2022.08.064. PMID:36436672. IF:2.100(Q2/5D).
01/01/2023
Neisseria meningitidis and the increase of oral sex. A case report
Borràs J., Alonso-Tarrés C., Vives A., Palou J.. Neisseria meningitidis and the increase of oral sex. A case report. Revista Internacional de Andrologia. 2023; 21(1)DOI:10.1016/j.androl.2021.02.010. PMID:36307367. IF:0.800(Q4/10D).
01/01/2023
Indications and histology of 489 orchiectomies analyzed by patient age
Fontanet S., Huguet J., Gaya J.M., Territo A., Gallioli A., Aumatell J., Algaba F., Palou J., Breda A.. Indications and histology of 489 orchiectomies analyzed by patient age. Actas Urologicas Espanolas. 2023; 47(7)DOI:10.1016/j.acuro.2022.10.004. PMID:. IF:(Q/D).
01/01/2023
Comment on: “Outcomes of kidney transplantation from uncontrolled donors after circulatory death vs. expanded-criteria or standard-criteria donors after brain death at an Italian Academic Center: a prospective observational study”
Piana A., Prudhomme T., Boissier R., Hevia V., Alba S., Breda A., Territo A.. Comment on: “Outcomes of kidney transplantation from uncontrolled donors after circulatory death vs. expanded-criteria or standard-criteria donors after brain death at an Italian Academic Center: a prospective observational study”. Minerva Urology And Nephrology. 2023; 75(4)DOI:10.23736/S2724-6051.23.05431-9. PMID:37530664. IF:(Q/D).
01/01/2023
Quality of life of patients with stone disease: timing, planning, strategies, and prevention of a systemic pathology
Esperto F., Pietropaolo A., Emiliani E., de Coninck V., Tailly T., Keller E.X., Talso M., Tonyali S., Sener E.T., Zeeshan Hameed B.M., Tzelves L., Ventimiglia E., Juliebø-Jones P., Faiella E., Mykoniatis I., Tsaturyan A., Scarpa R.M.. Quality of life of patients with stone disease: timing, planning, strategies, and prevention of a systemic pathology. Minerva Urology And Nephrology. 2023; 75(4)DOI:10.23736/S2724-6051.23.05435-6. PMID:37314814. IF:4.900(Q1/2D).
01/01/2023
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure
Sanz Gómez I., Huguet J., Bravo A., Robalino J., Rodríguez Faba Ó., Territo Á., Gaya J.M., Palou J., Breda A.. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. Clinical Genitourinary Cancer. 2023; 21(4)DOI:10.1016/j.clgc.2023.03.002. PMID:37076337. IF:2.300(Q2/5D).
01/01/2023
A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer
Grobet-Jeandin E., Lenfant L., Mir C., Giannarini G., Alcaraz A., Albersen M., Breda A., Briganti A., Rouprêt M., Seisen T., EAU Section of Oncological Urology (ESOU) Board. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. European Urology Oncology. 2023; 6(3)DOI:10.1016/j.euo.2023.02.008. PMID:36906510. IF:8.300(Q1/1D).
01/01/2023
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients with Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
Tyson M.D., Morris D., Palou J., Rodriguez O., Mir M.C., Dickstein R.J., Guerrero-Ramos F., Scarpato K.R., Hafron J.M., Messing E.M., Cutie C.J., Maffeo J.C., Raybold B., Chau A., Stromberg K.A., Keegan K.A.. Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients with Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. JOURNAL OF UROLOGY. 2023; 209(5)DOI:10.1097/JU.0000000000003195. PMID:37026631. IF:6.400(Q1/1D).